Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

NCT07485920 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT07485920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07485920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
January 31, 2030
Enrollment
20 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

limited-stage small cell lung cancer (ls-sclc)